BALYASNY ASSET MANAGEMENT L.P. - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.

Quarter-by-quarter ownership
BALYASNY ASSET MANAGEMENT L.P. ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q1 2023$3,649,092
+1365.5%
220,090
+780.4%
0.01%
+800.0%
Q3 2022$249,000
-33.2%
25,000
-32.0%
0.00%0.0%
Q1 2022$373,000
-54.1%
36,786
-24.5%
0.00%
-66.7%
Q4 2021$812,000
-77.2%
48,700
-2.6%
0.00%
-85.0%
Q4 2020$3,556,00050,0000.02%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders